# INHIBRX BIOSCIENCES, INC. (INBX) · Edgar & Edgarette company card

> Inhibrx Biosciences (INBX) grew revenue 550% in FY2025 to $1 million, operating margin -10387% against a -15.8% median for biological products, (no diagnostic substances), equity 5.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 2007919 · fiscal year ended 2025-12-31 · 3 audited years read · [page](https://www.pops4.com/boards/company/INBX) · [JSON](https://www.pops4.com/boards/company/INBX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1M |
| Revenue growth, 1 year | 550.0% |
| Revenue growth per year | -15.0% |
| Operating margin | -10386.5% (prior year -165724.0%) |
| Net margin | -10773.5% |
| Operating cash flow | −$130M |
| Capital spending | $31,000 |
| Free cash flow | −$130M |
| Cash | $124M |
| Long-term debt | $101M |
| Total assets | $146M |
| Total equity | $8M |
| Equity ÷ assets | 5.5% |
| Return on equity | -1752.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -7.18 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -10386.5% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $1.3M (FY2025), total debt $100.6M. Experience: revenue up 550.0% on the year, down 15.0% a year over 2 years; operating margin -10386.5%, up from -165724.0%. Soundness: equity 5.5% of assets, return on equity -1752.2%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $3.5M and $6.3M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -10386.5% against a -15.8% median; growth 550.0% against 21.4%.

Range logged 2026-09-20, receipt 922b97baae6d75ca, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-09-28 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000050/0002007919-26-000050-index.htm)
- 8-K · filed 2026-09-08 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000047/0002007919-26-000047-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/0002007919-26-000044-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000042/0002007919-26-000042-index.htm)
- 8-K · filed 2026-07-16 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000037/0002007919-26-000037-index.htm)
- 8-K · filed 2026-06-15 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/0002007919-26-000033-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0002007919.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2007919

## Cite

POPS4, Edgar & Edgarette: INHIBRX BIOSCIENCES, INC. (INBX) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/INBX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.